Challenges in chronic paediatric disease during the COVID-19 pandemic: diagnosis and management of inflammatory bowel disease in children

Many paediatric healthcare professionals are increasingly concerned about the long-term secondary impact of the COVID-19 pandemic on the care of children and young people (CYP) with chronic conditions. Those of us working in paediatric gastroenterology now lack the ability to provide the same level of diagnostic care and ongoing management to our patients, particularly the large number with inflammatory bowel disease (IBD). With all elective endoscopy cancelled, difficulty in obtaining day-case infusions and telemedicine becoming the norm, many professionals are justifiably uncomfortable. There is little known about the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on those CYP with IBD, or on patients with systemic immunosuppression, although the small amount of data derived thus far indicates mild disease in those <18 years.1 2 Whilst the pressures on diagnostic choices for patients.1 In Crohn’s disease, CYP patients have long been started on EEN as a first-line induction therapy. This strategy now appears to offer further benefits; not exposing patients to systemic immunosuppression while offering the potential of buying 4–8 weeks prior to consideration of immunosuppression or biologic therapy.

The risks of stopping treatment in CYP is considerable. The Chinese Society of Gastroenterology guidelines instructed clinicians to stop IBDM maintenance therapy during the initial COVID-19 outbreak. This guideline is polar opposite to recommendations from the UK, where the risk of disease flare is considered to be greater than that of infection with SARS-CoV-2.4 Interestingly, recent survey data from the ESPGHAN PORTO group reports monoclonal treatment was delayed in 79 children in China and South Korea, with 22% having relapse.1

We will be living with the direct, and indirect, effects of the SARS-CoV-2 virus for some time. The limited publications to date do not suggest an increased risk of COVID-19 in those with paediatric inflammatory bowel disease, however these are extremely preliminary and must be interpreted with caution.2 These problems in IBD will be echoed in many other chronic medical disorders of childhood where there is potential for secondary morbidity to exceed the primary morbidity from COVID-19. Highlighting these issues is highly relevant. Timely resourcing, consideration and action in the next phase of the pandemic response will minimise long-term harm to vulnerable CYP.

James J Ashton,1,2 Akshay Batra,2 Tracy A F Coelho,3 Nadeem A Afzal,2 R Mark Beattie3

1Human Genetics and Genomic Medicine, University of Southampton, Southampton, UK
2Department of Paediatric Gastroenterology, Southampton Children’s Hospital, Southampton, UK
3Correspondence to Professor R Mark Beattie, Department of Paediatric Gastroenterology, Southampton Children’s Hospital, Southampton SO16 6YD, UK; mark.beattie@uhs.nhs.uk

Twitter James J Ashton @James_ J Ashton and R Mark Beattie @RMBeattie50

Funding JIA is funded by an Action Medical Research training fellowship and by an ESPEN personal fellowship.

Competing interests None declared.

Provenance and peer review Not commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2020. No commercial use. See rights and permissions. Published by BMJ.